So far, prostate cancer immunotherapy has shown only modest benefits. To greatly improve outcomes, immunotherapy will need to be combined with other treatments, according to the authors of a recent review.
A study looking at the effect of genetic variations on the pharmacologic activity of metformin found that use of the drug was associated with an increased risk of prostate cancer overall and of high-grade prostate cancer.
Recent research shows that end-of-rotation transitions in care are associated with a significantly higher risk for in-hospital mortality.
“Ultimately, it is about culture. Efforts need to be made at all levels of medical education and training to create more supportive and nurturing educational settings.”
